公开(公告)号：US20180179596A1

公开(公告)日：2018-06-28

申请号：US15739961

申请日：2016-06-24

Applicant: MOR RESEARCH APPLICATIONS LTD.

Inventor： Smadar AVIGAD ,  Isaac YANIV ,  Lital SELA-TZURIANO

IPC: C12Q1/6886 ,  A61K38/50 ,  A61K45/06 ,  C07K14/47 ,  A61K31/603 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61K31/603 ,  A61K38/50 ,  A61K45/06 ,  C07K14/4702 ,  C12N2310/14 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57426 ,  G01N33/57484 ,  G01N2333/91057

Abstract: Described herein are methods of cancer diagnosis through monitoring the presence and activity of the KANSL1 gene, and particularly the effects of KANSL1 overexpression on specific histone acetylation. Cancer treatment with histone acetyltransferase inhibitors and deacetylase agents is also described.

公开(公告)号：US20170252364A1

公开(公告)日：2017-09-07

申请号：US15500456

申请日：2015-07-30

Applicant: MOR RESEARCH APPLICATIONS LTD.

Inventor： Smadar AVIGAD ,  Isaac YANIV ,  Keren SHICHRUR

IPC: A61K31/7105 ,  G01N33/574 ,  A61K39/395 ,  A61K31/4025 ,  C12Q1/68

CPC classification number: A61K31/7105 ,  A61K31/4025 ,  A61K39/3955 ,  C12N15/1137 ,  C12N2310/141 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57426 ,  G01N2800/54

Abstract: Provided herein are compositions for treatment of Acute Lymphoblastic Leukemia (ALL) and methods of their use, including inhibiting ALL relapse. Further provided herein are systems of treatment that are directed by a health care provider, and which combine prognostic methods for determining ALL relapse and the described treatments.

公开(公告)号：US20190388457A1

公开(公告)日：2019-12-26

申请号：US16567233

申请日：2019-09-11

Applicant: MOR RESEARCH APPLICATIONS LTD.

Inventor： Smadar AVIGAD ,  Isaac YANIV ,  Keren SHICHRUR

IPC: A61K31/7105 ,  G01N33/574 ,  C12Q1/6886 ,  A61K31/4025 ,  A61K39/395

Abstract: Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL), and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider, and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.

公开(公告)号：US20190167711A1

公开(公告)日：2019-06-06

申请号：US16272352

申请日：2019-02-11

Applicant: MOR RESEARCH APPLICATIONS LTD.

Inventor： Smadar AVIGAD ,  Isaac YANIV ,  Keren SHICHRUR

IPC: A61K31/7105 ,  C12Q1/6886 ,  A61P35/02

Abstract: Provided herein is the use of miR-451 as a biomarker in prognosis of anti-ALL treatment modalities, in early diagnosis of ALL relapse risk, and/or in identifying an ALL patient that can benefit from a treatment modality that affects one or more miR-451-related metabolic pathways.

公开(公告)号：US20170268070A1

公开(公告)日：2017-09-21

申请号：US15500104

申请日：2015-07-30

Applicant: MOR RESEARCH APPLICATIONS LTD.

Inventor： Smadar AVIGAD ,  Isaac YANIV ,  Keren SHICHRUR

IPC: C12Q1/68

CPC classification number: A61K31/7105 ,  A61K31/4025 ,  A61K39/3955 ,  C12N15/1137 ,  C12N2310/141 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57426 ,  G01N2800/54

Abstract: Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL), and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider, and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.